|
1
|
Howlader NNA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al; Cronin KA: SEER Cancer Statistics Review, 1975–2014. National Cancer Institute; Bethesda, MD: 2017, https://seer.cancer.gov/archive/csr/1975_2014/April 2–2018
|
|
2
|
Novo M, Castellino A, Nicolosi M, Santambrogio E, Vassallo F, Chiappella A and Vitolo U: High-grade B-cell lymphoma: How to diagnose and treat. Expert Rev Hematol. 12:497–506. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones JA, Drew J, Wu C, Mulvey E, et al: Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood blood. 2021011679. 2021. View Article : Google Scholar
|
|
4
|
Frazzi R, Zanetti E, Pistoni M, Tamagnini I, Valli R, Braglia L and Merli F: Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. Leuk Res. 57:89–96. 2017. View Article : Google Scholar
|
|
5
|
Ghaleb AM and Yang VW: Krüppel-like factor 4 (KLF4): What we currently know. Gene. 611:27–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, et al: DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 125:1922–1931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JPP and Lacorazza HD: Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. 31:1314–1324. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang H, Zhou LY, Guan ZB, Zeng WB, Zhou LL, Liu YN and Pan XY: Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis. PLoS One. 14:e02109432019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Özdemir İ, Pınarlı FG, Pınarlı FA, Aksakal FNB, Okur A, Uyar Göçün P and Karadeniz C: Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas. Pediatr Hematol Oncol. 35:131–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spiegel R, Soiferman D, Shaag A, Shalev S, Elpeleg O and Saada A: Novel Homozygous Missense Mutation in SPG20 Gene Results in Troyer Syndrome Associated with Mitochondrial Cytochrome c Oxidase Deficiency. JIMD Rep. 33:55–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patel H, Cross H, Proukakis C, Hershberger R, Bork P, Ciccarelli FD, Patton MA, McKusick VA and Crosby AH: SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet. 31:347–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tawamie H, Wohlleber E, Uebe S, Schmäl C, Nöthen MM and Abou Jamra R: Recurrent null mutation in SPG20 leads to Troyer syndrome. Mol Cell Probes. 29:315–318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M and Götze KS: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 8:712016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hagemann S, Heil O, Lyko F and Brueckner B: Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 6:e173882011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duncan CG, Kondilis-Mangum HD, Grimm SA, Bushel PR, Chrysovergis K, Roberts JD, Tyson FL, Merrick BA and Wade PA: Base-Resolution Analysis of DNA Methylation Patterns Downstream of Dnmt3a in Mouse Naïve B Cells. G3 (Bethesda). 8:805–813. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Rau R and Goodell MA: DNMT3A in haematological malignancies. Nat Rev Cancer. 15:152–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lyko F: The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat Rev Genet. 19:81–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N and Merli F: Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Int J Cancer. 132:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guan H, Xie L, Leithäuser F, Flossbach L, Möller P, Wirth T and Ushmorov A: KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood. 116:1469–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Küçük C, Hu X, Jiang B, Klinkebiel D, Geng H, Gong Q, Bouska A, Iqbal J, Gaulard P, McKeithan TW, et al: Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 21:1699–1711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mehdipour P, Murphy T and De Carvalho DD: The role of DNA-demethylating agents in cancer therapy. Pharmacol Ther. 205:1074162020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, et al: Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics. 8:792016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin P, Bartlett NL, Rivera IIR, Revuelta M, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Zhang L, Zhai M, et al: A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma. Blood. 130 (Suppl 1):1922017.
|
|
25
|
Cerchietti L and Leonard JP: Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: Beyond R-CHOP. Hematology (Am Soc Hematol Educ Program). 2013:591–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hatzi K and Melnick A: Breaking bad in the germinal center: How deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med. 20:343–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Basso K and Dalla-Favera R: Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. 247:172–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, Jaye DL, Mav D, Shah R, Li L, et al: DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med. 207:1939–1950. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature. 405:486–489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
López-Moyado IF, Tsagaratou A, Yuita H, Seo H, Delatte B, Heinz S, Benner C and Rao A: Paradoxical association of TET loss of function with genome-wide DNA hypomethylation. Proc Natl Acad Sci USA. 116:16933–16942. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu K, Wang YF, Cantemir C and Muller MT: Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol. 23:2709–2719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Z, Wang W, Xie X, Song Y, Dang C and Zhang H: Methylation-induced silencing of SPG20 facilitates gastric cancer cell proliferation by activating the EGFR/MAPK pathway. Biochem Biophys Res Commun. 500:411–417. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rezvani N, Alibakhshi R, Vaisi-Raygani A, Bashiri H and Saidijam M: Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method. Oncol Lett. 13:3277–3284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, et al: Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 89:154–164. 2004.PubMed/NCBI
|
|
35
|
Kristensen LS, Treppendahl MB, Asmar F, Girkov MS, Nielsen HM, Kjeldsen TE, Ralfkiaer E, Hansen LL and Grønbæk K: Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep. 3:27892013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M and Korbi S: Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 19:1774–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H and Aozasa K: Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol. 86:557–564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giachelia M, Bozzoli V, D'Alò F, Tisi MC, Massini G, Maiolo E, Guidi F, Cupelli E, Martini M, Larocca LM, et al: Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. J Mol Diagn. 16:467–476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harsløf LB, Pedersen OB, De Nully Brown P and Grønbæk K: Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics. 8:952016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morales-Martinez M, Vega GG, Neri N, Nambo MJ, Alvarado I, Cuadra I, Duran-Padilla MA, Huerta-Yepez S and Vega MI: MicroRNA-7 Regulates Migration and Chemoresistance in Non-Hodgkin Lymphoma Cells Through Regulation of KLF4 and YY1. Front Oncol. 10:5888932020. View Article : Google Scholar : PubMed/NCBI
|
